CAFs have a marked immunomodulating secretome typically activated by IL1β, FGF2, and TGFβ and containing IL6, CXCL8, CXCL1, CCL2, and IFNβ and inflammatory niches have been reported to adapt to and confer drug tolerance to BRAF and MEK inhibitors early during treatment because melanoma cells survive upregulating Bcl2 [283]. This evidence concerns the gene BRAF and melanoma.